

**File S2.** Cox regression analyses about local progression for all patients treated with SABR.

	Univariate analysis		Multivariate analysis	
	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Age (years)		0.352		
Sex (male)	2.238 (0.971-5.157)	0.059		0.096
ASA		0.213		
ECOG $\geq$ 2	2.768 (0.793-9.665)	0.110		
Primary cancer group of modified Tokuhashi score		0.001		<b>&lt;0.001</b>
Kidney, uterus <sup>a</sup>	3.381 (0.907-12.611)	0.070		0.051
Liver, gallbladder <sup>a</sup>	12.994 (3.459-48.813)	<0.001	<b>90.548 (10.146-808.107)</b>	<b>&lt;0.001</b>
Lung, pancreas,etc <sup>a</sup>	3.780 (1.078-13.251)	0.038		0.051
Extraspinal bone metastasis		0.045		<b>0.048</b>
1-2 <sup>b</sup>		0.331		0.968
$\geq$ 3 <sup>b</sup>	15.505 (1.668-144.133)	0.016	<b>81.440 (5.402-1227.676)</b>	<b>0.001</b>
Internal organ metastasis		0.013		0.268
Removable <sup>c</sup>		0.352		0.431
Unremovable <sup>c</sup>	2.801 (1.131-6.936)	0.026		0.113
Radioresistancy	1.915 (0.824-4.450)	0.131	<b>65.106 (7.424-570.990)</b>	<b>&lt;0.001</b>
Location of spinal metastasis		0.609		
Thoracic <sup>d</sup>		0.323		
Cervical <sup>d</sup>		0.780		
Prior radiotherapy	4.381 (1.253-15.324)	0.021		0.064
Prior adjuvant Tx.		0.865		
Total radiation dose		0.227		
Fraction		0.204		
High bilsky grade	2.862 (1.207-6.788)	0.017		0.305
Bilsky grade 3	2.991 (1.148-7.793)	0.025	<b>4.013 (1.191-13.473)</b>	<b>0.025</b>
Size > 30mm		0.423		
Time from diagnosis to treatment (month)		0.229		

<sup>a</sup> Hazard ratio compared to primary cancer origin of thyroid, breast, prostate carcinoid tumour, <sup>b</sup> Hazard ratio compared to no extraspinal bone metastasis, <sup>c</sup> Hazard ratio compared to no internal organ metastasis, <sup>d</sup> Hazard ratio compared to lumbar.